Skip to main content
Premium Trial:

Request an Annual Quote

Seegene Licenses Multiplex Assay Technologies to BioMerieux for Food Safety Testing

NEW YORK (GenomeWeb News) – Seegene said today that BioMérieux has taken a license to its DPO and TOCE technologies for the development of multiplexed molecular tests for food safety.

Financial terms of the agreement were not disclosed.

Seegene's DPO (dual-priming oligonucleotide) and TOCE (tagging oligonucleotide capture and extension) technologies enable highly multiplexed assays based on real-time PCR.

DPO can be used to block extension of non-specifically primed templates, generating consistently high specificity, while TOCE enables simultaneous multiplexed assays by separating genes that have been amplified by real-time PCR technology based on differences in their melting temperatures, Seegene said.

"We believe that the adoption of our leading multiplexing technology will curtail future food contamination outbreaks, save lives, and help to grow this important market," Seegene CEO and CTO Jong-Yoon Chun said in a statement.

Seegene last year inked a similar licensing agreement for food safety testing with DuPont Nutrition & Health.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.